The title compound, C18H17BrO6 （Mr = 409.23）, was synthesized as angiogenesis inhibitor and structurally characterized by ^1H-NMR, ^13C-NMR, MS, elemental analysis and X-ray single-crystal diffraction. Structure analysis indicates that the title compound is of triclinic, space group P1^-, with a = 8.100（3）, b = 10.536（4）, c = 11.689（5）A, a = 67.405（7）, βl = 69.736（3）, γ = 88.510（5）°, V = 857.3（5） A^3, Z = 2, Dc = 1.585 g/cm^3, μ = 2.429 mm^-1, F（000） = 416, the finial R = 0.0356 and wR = 0.0929 for 2541 observed reflections. The bond lengths of C（7）-C（16） proved that the title compound possesses coumarin rather than flavone scaffold.
3-（4-Hydroxyphenyl）-4-methyl-6-methoxy-7-hydroxycoumarin （2a） and its analogues with different substituents at the p-position of 3-phenyl group were designed and synthesized as the non-steroidal analogues of 2-methoxyestradiol （2-ME 1）. The desired compounds were synthesized via a novel and simple route and the effects of specific substituents on their antiangiogenesis activities were investigated with Human umbilical vein endothelial cells （HUVECs） proliferation assays. Preliminary biological screening showed that compounds 2a and 2d （IC50 = 61.0 and 76.7 ktM, respectively） have potential anti-angiogenesis activities. The bulk of the group at the p-position of 3-phenyl group likely play an important role in their activities.
